News und Analysen

Dividend stocks are potent instruments for building wealth. A staggering 85% of the S&P 500's total returns since 1960 have emanated from dividend payouts, according to a report by Hartford Funds.

A

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q1 2024 Earnings CallApr 16, 2024, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q1 2024 Earnings CallApr 16, 2024, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of UnitedHealth Group (NYSE: UNH) were jumping 5.7% higher as of 11:17 a.m. ET on Tuesday after rising as much as 7.7% earlier in the day. The solid gain came after the giant healthcare

Shares of UnitedHealth Group (NYSE: UNH) were jumping 5.7% higher as of 11:17 a.m. ET on Tuesday after rising as much as 7.7% earlier in the day. The solid gain came after the giant healthcare

Investors looking for stocks that can produce heaps of passive income want to look at recent activity from some of the world's most successful investors. Billionaire hedge fund manager Ken Griffin

Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a

Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a

Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a

Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to

Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to

The bull market is roaring higher, and many growth stocks have led the gains -- but this doesn't mean your opportunity to buy growth stocks for a good price is over. Plenty of players with great

In biopharma, it sometimes makes sense for companies to spend a lot of money on buying or developing technical capabilities that seem to be counterproductive at first glance. For instance, on April

Big pharma stocks like AbbVie (NYSE: ABBV) usually aren't high on the list that investors look to for opportunities that could make them into millionaires. After all, they aren't typically in the

If there is one thing Bluebird Bio (NASDAQ: BLUE) and Novavax (NASDAQ: NVAX) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop

Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain?

Three Motley Fool contributors think

The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).

Vertex recently offered

The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).

Vertex recently offered

The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).

Vertex recently offered

Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (NASDAQ: ANAB). The company's shares closed the week almost 8% higher in price, according to

Investing for the long term, as opposed to day trading, offers many benefits. Holding shares of companies for a while arguably brings more peace of mind, some tax advantages, and the ability for

Investing for the long term, as opposed to day trading, offers many benefits. Holding shares of companies for a while arguably brings more peace of mind, some tax advantages, and the ability for

In just the past 12 months, Novavax (NASDAQ: NVAX) stock has plummeted 48% in value. The once-promising COVID vaccine maker has struggled mightily; it was late to getting a vaccine approved and to